ZyVersa Therapeutics, Inc. (ZVSA)
ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. Furthermore, ZyVersa is advancing IC 100, a pioneering inflammasome ASC inhibitor positioned to tackle a wide array of inflammatory conditions. The company maintains its corporate headquarters in Weston, Florida.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
ZyVersa Therapeutics, Inc.
OTC:ZVSAHealthcare · Biotechnology
+0.00%$0.0010
Mkt Cap$8K
Float7.19M
O/S8.1M
Inst Own0.0%
Dilution
Delisting Issues Timeline
Financials Summary
Revenue$0
Net Income-$24.95M
Total Assets$347.9M
Free Cash Flow-$5.11M
Debt & Equity
Total Debt$0
Total Equity-$12.39B
Shares Outstanding
Short Interest
Split History2 splits · 2 reverse
- 1:10Reverse splitApr 26, 202410 shares → 1
- 1:35Reverse splitDec 5, 202335 shares → 1
Balance Sheet Details
Assets$347.9M
Liabilities$12.73B
Accounts Receivable$0
Accounts Payable$10.12M
Inventory$0
PP&E (Net)$0
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - |
| Cost of Revenue | $0 | $7K | $10K | $10K | $10K | $10K |
| Gross Profit | $0 | -$7K | -$10K | -$10K | -$10K | -$10K |
| Gross Margin | - | - | - | - | - | - |
| Research and Development | $1.11B | $1.78B | $3.21M | $5.41M | $2.12M | $6.47M |
| Selling, General, and Administrative | $5.73B | $7.36B | $11.2M | $7.61M | $5.58M | $5.36M |
| Other | -$6.84B | -$9.13B | $0 | $810K | $0 | $0 |
| Total Operating Expenses | $6.84M | $9.13M | $14.41M | $13.82M | $7.7M | $11.83M |
| Operating Income (EBIT) | -$6.84M | -$9.14B | -$14.42M | -$13.83M | -$7.7M | -$11.83M |
| Operating Margin | - | - | - | - | - | - |
| Interest Expense | $513K | $270K | $0 | $428K | $821K | $516K |
| Interest Income | $0 | $0 | $457 | $428 | $821 | $516 |
| Other Income (Expense) | -$18.96M | -$283.35M | -$93.33M | -$1.03M | -$380K | -$850K |
| Income Before Tax (EBT) | -$25.8M | -$9.42B | -$107.75M | -$14.87M | -$8.08M | -$12.68M |
| Income Tax Expense | -$852K | -$6.75M | -$9.46M | -$745K | $0 | $0 |
| Net Income | -$24.95M | -$9.41B | -$98.3M | -$14.05M | -$8.08M | -$12.68M |
| Net Income Margin | - | - | - | - | - | - |
| Supplementary Data | ||||||
| EPS | -4.18 | -8.48 | -1089.66 | -930.25 | -173.66 | -272.45 |
| Diluted EPS | -4.18 | -8.48 | -1089.66 | -930.25 | -173.66 | -272.45 |
| Weighted Average OS | 5.96B | 1.11M | 97,503 | 25,948 | 46,552 | 46,552 |
| EBITDA | -$25.29M | -$9.14B | -$107.74M | -$14.43M | -$7.25M | -$12.16M |
| EBITDA Margin | - | - | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Assets | ||||||
| Current Assets | ||||||
| Cash and Cash Equivalents | $101.78M | $1.53M | $3.14M | $5.9M | $329K | $175K |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $101.78M | $1.53M | $3.14M | $5.9M | $329K | $175K |
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $246.12M | $185K | $215K | $460K | $483K | $164K |
| Total Current Assets | $347.9M | $1.72M | $3.35M | $6.36M | $812K | $339K |
| Long-Term Assets | ||||||
| Property, Plant & Equipment Net | $0 | $0 | $15K | $116K | $28K | $38K |
| Goodwill | $0 | $0 | $0 | $11.9M | $0 | $0 |
| Intangible Assets | $0 | $18.65M | $18.65M | $100.09M | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $0 | $236K | $98K | $47K | $287K | $308K |
| Total Long-Term Assets | $0 | $18.88M | $18.76M | $112.14M | $314K | $346K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $347.9M | $20.6M | $22.11M | $118.51M | $1.13M | $686K |
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts Payable | $10.12M | $9.34M | $8.43M | $6.03M | $2M | $2.31M |
| Short-Term Debt | $0 | $0 | $9K | $109K | $9.15M | $2.13M |
| Current Income Tax Payable | $0 | $0 | $0 | $107K | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $17K | $21K |
| Other Current Liabilities | $12.72B | $855K | $1.09M | $1.36M | $2.46M | $2.18M |
| Total Current Liabilities | $12.73B | $11.23M | $10.19M | $8.19M | $13.63M | $7.56M |
| Long-Term Liabilities | ||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $1.69M |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $852K | $845K | $10.32M | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Long-Term Liabilities | $0 | $852K | $845K | $10.32M | $0 | $1.69M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $12.73B | $12.08M | $11.04M | $18.51M | $13.63M | $9.24M |
| Stockholders' Equity | ||||||
| Preferred Stock | $0 | $0 | $0 | $331K | $331K | $331K |
| Common Stock | $809 | $251 | $405 | $902 | $242 | $242 |
| Retained Earnings | -$137.58M | -$112.63M | -$103.22M | -$4.92M | -$52.9M | -$44.81M |
| Comprehensive Income & Other | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Stockholders' Equity | -$12.25B | $121.15M | $114.29M | $104.91M | $40.4M | $36.25M |
| Total Equity | -$12.39B | $8.52M | $11.07M | $99.99M | -$12.5M | -$8.56M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $347.9M | $20.6M | $22.11M | $118.51M | $1.13M | $686K |
| Supplementary Data | ||||||
| Total Debt | $0 | $0 | $9K | $109K | $9.15M | $3.82M |
| Net Debt | -$101.78M | -$1.53M | -$3.13M | -$5.79M | $8.82M | $3.64M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Operating Activities | ||||||
| Net Income | -$24.95M | -$9.41M | -$98.3M | -$14.05M | -$8.08M | -$12.68M |
| Depreciation & Amortization | $0 | $7K | $10K | $10K | $10K | $10K |
| Deferred Income Tax | -$852K | $7K | -$9.48M | -$745K | -$442K | $334K |
| Stock-Based Compensation | $223K | $706K | $1.19M | $3.52M | $4.14M | $3.83M |
| Changes in Working Capital: | ||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $689K | $751K | $2.41M | $6.62M | -$312K | -$601K |
| Other Working Capital | $832K | $179K | $195K | $1.67M | -$708K | $3.71M |
| Total Working Capital Change | $1.52M | $930K | $2.6M | $8.29M | -$1.02M | $3.11M |
| Other Non-Cash Items | $18.95M | $205K | $95.25M | -$1.92M | $318K | $288K |
| Net Cash from Operating | -$5.11M | -$7.56M | -$8.72M | -$4.89M | -$5.08M | -$5.11M |
| Investing Activities | ||||||
| Capital Expenditures | $0 | $0 | $0 | $0 | $0 | $0 |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing Activities | ||||||
| Debt Repaid | - | - | - | - | - | -$1.69M |
| Common Stock Issuance | $4.05M | $5.95M | $16.66M | $1.87M | $0 | $3M |
| Common Stock Repurchases | $0 | $0 | -$10.7M | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$367K | -$628K | -$1.46M | -$99K | $5K | -$126K |
| Net Cash from Financing | $3.69M | $5.95M | $5.96M | $1.87M | $5.23M | $4.56M |
| Forex Effect | $0 | $0 | $0 | $8.6M | $0 | $0 |
| Net Change in Cash | -$1.43M | -$1.61M | -$2.76M | $5.57M | $154K | -$550K |
| Supplementary Data | ||||||
| Operating Cash Flow | -$5.11M | -$7.56M | -$8.72M | -$4.89M | -$5.08M | -$5.11M |
| Capital Expenditure | $0 | -$3 | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$5.11M | -$7.56M | -$8.72M | -$1.49M | -$5.08M | -$5.11M |
| Cash at Beginning | $1.53M | $3.14M | $5.9M | $329K | $175K | $724K |
| Cash at End | $102K | $1.53M | $3.14M | $699K | $329K | $175K |